The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis

Joint Bone Spine

Volumn 78, Issue 2, 2011, Pages 188-193

  Kang, Kwi Young ^a   Lee, Kwan Yong ^b   Kwok, Seung Ki ^b   Ju, Ji Hyeon ^b   Park, Kyung Soo ^b   Hong, Yeon Sik ^b   Kim, Ho Youn ^b   Park, Sung Hwan ^b  

^a Chungbuk National University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Ankylosing spondylitis; Anti TNF agent; Bisphosphonate; Inflammation; Osteoporosis

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CLINICAL FEATURE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BONE DENSITY; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FEMUR; HUMANS; IMMUNOGLOBULIN G; LUMBAR VERTEBRAE; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952242241     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.05.010     Document Type: Article

References (40)

1. Van der Linden S.L., Van der Heijde D.H., Maksymowych W.P. Ankylosing Spondylitis. Kelley's Textbook of Rheumatology 2008, Saunders, Philadelphia, p. 1169-89. 8th ed. S.F. Gary (Ed.).
2. Donnelly S., Doyle D.V., Denton A., et al. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994, 53:117-121.
3. Ralston S.H., Urquhart G.D., Brzeski M., et al. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990, 300:563-565.
4. Ghozlani I., Ghazi M., Nouijai A., et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 2009, 44:772-776.
5. Cooper C., Carbone L., Michet C.J., et al. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994, 21:1877-1882.
6. El Maghraoui A., Borderie D., Cherruau B., et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999, 26:2205-2209.
7. Karberg K., Zochling J., Sieper J., et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005, 32:1290-1298.
8. Toussirot E., Michel F., Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 2001, 40:882-888.
9. Calin A. Osteoporosis and ankylosing spondylitis. Br J Rheumatol 1991, 30:318-319.
10. Mullaji A.B., Upadhyay S.S., Ho E.K. Bone mineral density in ankylosing spondylitis. DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br 1994, 76:660-665.
11. Will R., Palmer R., Bhalla A.K., et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event?. Lancet 1989, 2:1483-1485.
12. Singh A., Bronson W., Walker S.E., et al. Relative value of femoral and lumbar bone mineral density assessments in patients with ankylosing spondylitis. South Med J 1995, 88:939-943.
13. Bessant R., Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis?. J Rheumatol 2002, 29:1511-1519.
14. Bischoff L., Derk C.T. Premenopausal osteoporosis. Minerva Med 2008, 99:55-63.
15. Briot K., Gossec L., Kolta S., et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving antitumor necrosis factor-alpha treatment. J Rheumatol 2008, 35:855-861.
16. Demis E., Roux C., Breban M., et al. Infliximab in spondylarthropathy - influence on bone density. Clin Exp Rheumatol 2002, 20:S185-S186.
17. Woo J.H., Lee H.J., Sung I.H., et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007, 34:1753-1759.
18. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
19. Wanders A.J., Landewe R.B., Spoorenberg A., et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology Clinical Trials filter. Arthritis Rheum 2004, 50:2622-2632.
20. Lewiecki E.M., Gordon C.M., Baim S., et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008, 43:1115-1121.
21. Gratacos J., Collado A., Pons F., et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 1999, 42:2319-2324.
22. Sivri A., Kilinc S., Gokce-Kutsal Y., et al. Bone mineral density in ankylosing spondylitis. Clin Rheumatol 1996, 15:51-54.
23. Franck H., Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993, 52:343-346.
24. Devogelaer J.P., Maldague B., Malghem J., et al. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual-photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992, 35:1062-1067.
25. Aydin T., Karacan I., Demir S.E., et al. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels. Clin Endocrinol 2005, 63:467-469.
26. Raisz L.G. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988, 318:818-828.
27. Lange U., Teichmann J., Strunk J., et al. Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 2005, 16:1999-2004.
28. Maillefert J.F., Aho L.S., El Maghraoui A., et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001, 12:605-609.
29. Bal A., Unlu E., Bahar G., et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007, 26:211-215.
30. Bessant R., Harris C., Keat A. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol 2003, 30:779-782.
31. Tanaka Y., Nakayamada S., Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:325-328.
32. Van Offel J.F., Schuerwegh A.J., Bridts C.H., et al. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 2001, 19:13-20.
33. Pennanen N., Lapinjoki S., Urtti A., et al. Effect of liposomal and free bisphosphonates on the IL-1 beta. IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995, 12:916-922.
34. Stevenson P.H., Stevenson J.R. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986, 38:227-233.
35. Cecchini M.G., Felix R., Fleisch H., et al. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987, 2:135-142.
36. Sansoni P., Passeri G., Fagnoni F., et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995, 10:1719-1725.
37. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002, 46:766-773.
38. Gratacos J., Collado A., Filella X., et al. Serum cytokines (IL-6, TNF-alpha. IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994, 33:927-931.
39. Sonel B., Tutkak H., Duzgun N. Serum levels of IL-1 beta, TNF-alpha. IL-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 2002, 69:463-467.
40. Briot K., Garnero P., Le Henanff A., et al. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving antitumour necrosis factor {alpha} treatment. Ann Rheum Dis 2005, 64:1137-1140.